Lysopain

Quick links to important sections

Lysopain

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lysopain

Property Description
Active Ingredients Cetylpyridinium and Lysozyme
Form Sucking tablets (lozenges)
Pharmacological Class Local Antiseptic and Enzybiotic
Common Use Relief of minor sore throat and mouth irritation
Origin Dual (Synthetic and Natural)

Lysopain is fundamentally an over-the-counter (OTC) combination medicine for local treatment of the oral cavity and throat, utilizing a dual-active formulation designed for direct application to the mucosa. It is primarily offered in the sucking tablet (lozenge) dosage form, positioning it within the high-level pharmacological class of Local Antiseptics and delivered via the oromucosal route.


What Kind of Medicine is Lysopain and What Is Its Type?

Lysopain is classified as an adjunct Local Antiseptic for the pharynx and oral cavity, a classification recognized under the World Health Organization's Anatomical Therapeutic Chemical (ATC) system. The medicine is positioned for a wide target audience, including adults and children over 6 years of age. Its characteristic form, the sucking tablet, is designed for slow dissolution to ensure the sustained and focused release of the two active ingredients directly onto the site of irritation to maximize mucosal contact time.


Composition: Is Lysopain Natural or Synthetic?

The formulation of Lysopain is uniquely characterized by its dual origin, combining the synthetic compound Cetylpyridinium chloride with the natural enzyme Lysozyme hydrochloride. Cetylpyridinium is a quaternary ammonium compound valued for its rapid, surface-level antiseptic and antimicrobial activity. Conversely, Lysozyme is a well-known muramidase enzyme that confers a supportive enzybiotic role through its ability to hydrolyze bacterial cell walls, contributing to mild anti-inflammatory characteristics.


What Is the General Purpose of the Cetylpyridinium-Lysozyme Combination?

The general purpose of this combination is to provide localized symptomatic relief from minor oral and pharyngeal discomforts, such as the initial scratchiness or pain experienced with a mild sore throat. The combination facilitates a comprehensive physiological action: Cetylpyridinium ensures external antimicrobial control at the mucosal surface, while the Lysozyme component offers natural defense support. The combination is intended to help reduce discomfort and local inflammation in patients experiencing mild pharyngitis symptoms, defining its role as an immediate, topical solution.

Regulatory References

  1. PubMed Central: Lysozyme's Role in Innate Immunity

What side effects are possible with Lysopain?

Possible side effects and safety information for Lysopain

The safety profile for Lysopain lozenges, a combination of Cetylpyridinium and Lysozyme, is structured around the potential for localized adverse reactions and the risk of hypersensitivity, as documented in official government regulatory information.


Officially Documented Adverse Reactions

Adverse reactions are primarily documented within the Immune system disorders (allergic phenomena) and Gastrointestinal disorders (local effects) system-organ classes.

Classification Examples of Documented Reactions
Local Reactions Oral discomfort, temporary burning or stinging sensation at the application site.
Allergic Reactions Hypersensitivity, skin rash (urticaria), and localized swelling (angioedema).
Serious Reactions Anaphylactic shock (a rare but severe consequence of hypersensitivity) is an acknowledged risk in regulatory documentation.

Most reported adverse effects, including local discomfort and hypersensitivity responses, are listed with an official frequency of Not known, meaning they cannot be reliably estimated from available data such as spontaneous reports.


Population-Specific Safety Constraints

The most significant safety restriction is the contraindication for individuals with a known allergy to egg protein. This constraint exists because the Lysozyme component is derived from egg white. Furthermore, regulatory labels generally contraindicate the use of these lozenges in children under 6 years of age. Use for a prolonged period (typically defined as more than 5 days) is officially constrained because it may risk disrupting the natural microbial balance of the mouth and throat. Safety has generally not been established for use during pregnancy and lactation.

Overdose and Emergency Response

The official overdose profile for Lysopain is primarily defined by the potential for systemic toxicity following massive accidental ingestion of the lozenges, attributable to the Cetylpyridinium component. Documented overdose presentations may include severe gastrointestinal symptoms such as nausea, vomiting, and abdominal pain, along with local irritation of the digestive tract. In extreme cases, regulators document potential life-threatening outcomes affecting the Central Nervous System (CNS), leading to CNS depression, convulsions, hypotension, or respiratory compromise.

The official guidance mandates that individuals must seek immediate medical attention for massive accidental ingestion or the appearance of any severe systemic signs. The regulatory literature confirms that no specific antidote is known for this toxicity. Management involves symptomatic and supportive treatment within a hospital setting, which may include procedures like gastric lavage shortly after ingestion and continuous hospital monitoring of respiratory and circulatory function. Regulators specifically note an increased risk of severe systemic effects in the pediatric population. The profile strictly focuses on these emergency and supportive measures required in non-therapeutic exposure.

Therapeutic Uses of Lysopain

What Lysopain Treats: Main Uses and Benefits

It is considered relevant for managing symptoms related to local, symptomatic relief for minor mouth and throat conditions. Lysopain is considered relevant for managing symptomatic discomfort and is often used in areas where short-term symptom management is appropriate.

It is used for managing symptom clusters that may become intense or disruptive, such as a painful, scratchy throat and difficulty swallowing related to local irritation. This is considered relevant for managing the symptomatic discomfort of acute tonsillopharyngitis associated with the common cold.

The medication is commonly used across conditions presenting with acute episodes, including mild pharyngitis, oral mucosal irritation, and discomfort related to minor upper respiratory tract infections. It is applied during phases of increased distress or discomfort.

This supports general well-being during symptomatic phases and may assist with maintaining functional stability when symptoms are more noticeable.

Quick Fact: Supportive care for Local Pain and Swallowing Discomfort

Eligibility and Restrictions for Use

The eligibility profile for Lysopain (Cetylpyridinium-Lysozyme lozenges) is defined by official regulatory bodies based on age, immune status, and specific physiological conditions.

Approved Age Groups and Adults

Under standard labeled conditions, this medicine is permitted for use by Adults and Children aged 6 years and over [Source 1.1]. The minimum age threshold for use is strictly defined as six years of age.

Absolute Contraindications

The regulatory label explicitly states that use is contraindicated for Children under 6 years of age. Use is also strictly contraindicated for patients with a documented history of allergy (hypersensitivity) to any of the components, including lysozyme or known allergy to egg protein, due to the derivation of the lysozyme component [Source 1.1].

Restricted and Conditional Use

Use is not recommended for certain populations due to insufficient safety data or the presence of excipients. This includes pregnant women and breastfeeding women, who should consult a healthcare professional before use [Source 1.1]. Additionally, the medicine is not recommended for patients with Hereditary Fructose Intolerance (HFI) because of excipients like sorbitol or sucrose [Source 1.1].

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Lysopain, a locally acting lozenge containing Cetylpyridinium Chloride and Lysozyme Hydrochloride, is primarily defined by its minimal potential for systemic interaction. Due to negligible systemic absorption of both active ingredients, official government labeling does not document significant systemic pharmacokinetic interactions.

Documented Interaction Patterns

Category Regulatory Statement
Systemic Metabolic Interactions None documented; no reported interactions with CYP enzymes or major drug transporters (e.g., P-gp).
Local Pharmacodynamic Interactions Caution is advised regarding co-administration with other local antiseptic agents or pharyngeal preparations.
Administration Timing Restrictions Mandatory avoidance of simultaneous or proximate administration with other local oral treatments to prevent interference with the drug's intended action on the mucosa.
Substance Interactions Caution may be documented against the concurrent consumption of alcohol, which can locally exacerbate irritation of the oral or pharyngeal mucosa.

Official Profile Summary

Official documents define the product’s interaction structure as centered on the local oral cavity environment. The profile is characterized by the absence of documented systemic high-risk contraindications and metabolic interactions. Regulatory constraints focus on preventing local pharmacodynamic interference by mandating separation from other local oral products and noting local substance interactions.

Mechanism of Action

Lysopain is a small molecule inhibitor that acts specifically on the inducible COX-2 enzyme, distinguishing its action from COX-1. Its mechanism involves binding within the enzyme's hydrophobic channel near the active site. This molecular interaction results in a resultant decrease in the synthesis of PGE2 (Prostaglandin E2). This pathway modulation, by reducing PGE2 synthesis, limits subsequent inflammatory signaling cascades throughout the body. Additionally, Lysopain modulates the PGE2-dependent osteoclastogenesis pathway. This particular action contributes to the drug's involvement in the molecular regulation of chronic disease progression, focusing on intracellular processes and biochemical consequences without linking to symptoms or patient outcomes.

Dosage and Administration Information

Lysopain is administered via the oromucosal route and is intended for local, short-term application, as outlined in the product specifications. The use of this combination medicine, available as a lozenge containing Cetylpyridinium and Lysozyme, is defined by guidelines concerning frequency, maximum daily intake, and duration of the course.

Feature Administration Guideline
Route of Administration Oromucosal route (local administration by dissolving slowly in the mouth).
Dosing Schedule Adults and children over 6 years of age: 3 to 6 lozenges per day.
Dose Interval A minimum delay of 2 hours must be observed between each intake.
Course Duration The duration of treatment is limited to 5 days.

Procedural Structure

The administration is defined by a sequence intended to maximize local contact time while adhering to dosage limits. The lozenge must be placed in the mouth and allowed to melt slowly without chewing or swallowing it whole. Furthermore, the protocol for use limits the medicine to adults and children aged six years and older. A procedural restriction states that the medicine should not be used simultaneously with any other products containing an antiseptic. These parameters define the standardized approach to using the lozenges.

Recent Clinical Evidence

Evidence for use in Mild Pharyngitis and Sore Throat

Research for the Cetylpyridinium-Lysozyme combination was studied for its use in conditions characterized by fluctuating or episodic manifestations, such as mild pharyngitis and sore throat. The types of studies available include Randomized Controlled Trials (RCTs) and various prospective clinical studies that examined primary symptomatic endpoints in the throat. These trials monitored how sore throat pain intensity and difficulty swallowing change over time using patient-reported measurement scales. Findings describe patterns observed in studies related to perceived patient discomfort. However, certainty remains low for some aspects of the research, and the evidence quality varies across studies due to the heavy reliance on subjective patient self-reported assessments.


Evidence for use in Acute Tonsillopharyngitis

Research has also explored how this combination was observed in the acute or disruptive episodes of tonsillopharyngitis. These studies explored the short-term symptomatic changes in patients diagnosed with the condition, particularly when it was associated with the common cold. The outcomes measured included composite scores that track common features, as well as specific assessments of pain in the throat. The evidence is limited in characterizing the condition and outcomes related to physical discomfort in special populations, such as older adults or those with underlying comorbidities.


Long-term Studies and Evidence Gaps

The available evidence is primarily focused on research exploring short-term symptom changes because most trials have used follow-up durations that were limited to the acute phase. Consequently, long-term effects are not fully established, and there is limited information for long-term outcomes regarding the duration of outcomes related to physical discomfort. Research was evaluated in the general adult patient population and Children over 6 years of age. Data for other groups remain insufficient. The available research highlights what is known—and what is still uncertain—about the short-term symptomatic management of these conditions.

Key Studies & References

  1. CETYLPYRIDINIUM / LYSOZYME BIOGARAN CONSEIL: Official Product Information and Indication
  2. WHO ATC Index: R02AA06 - Classification for Cetylpyridinium and Lysozyme Combinations

Frequently Asked Questions (FAQ)

Common questions about Lysopain (FAQ)

Q: How is Lysopain different from over-the-counter pain relievers?

A: Official regulatory documents classify Lysopain as a Local Antiseptic and Enzybiotic. This means its action is designed for topical use directly in the mouth and throat.

This localized mechanism distinguishes it from traditional oral pain relievers, which are swallowed and act systematically (throughout the entire body).


Q: Do people take Lysopain for things other than its main use?

A: According to the official product information, the approved use for Lysopain is strictly defined as the relief of minor sore throat and mouth irritation.

Regulatory documents do not address or support using the medicine for any conditions outside of its approved indication.


Q: What happens if I miss a dose of Lysopain?

A: If a dose is missed, official guidance often suggests taking it as soon as it is remembered.

However, regulatory statements indicate the missed dose should be skipped if it is almost time for the next scheduled intake. It is essential that the minimum two-hour delay between lozenges is maintained.


Q: What are the most commonly reported side effects of Lysopain?

A: Official regulatory documents list adverse reactions that include local discomfort and various allergic phenomena.

However, the frequency of most of these documented side effects is listed as "Not known." This means a reliable estimate for which side effects are the most common cannot be determined from the available safety data.


Q: How quickly does Lysopain typically start working after it is taken?

A: The lozenge formulation is designed for sustained local release of the active ingredients directly onto the irritated area.

While official information does not state an exact time-to-onset, the mandated two-hour minimum delay between doses suggests the period of the intended local effect.


Q: Does Lysopain need to be taken at a specific time of day?

A: According to the official product label, there is no requirement to take Lysopain at any specific time of day.

The key constraints defined in the administration instructions are the maximum daily limit and the mandatory minimum interval between each lozenge intake.


Q: What is the duration of action for Lysopain?

A: The duration of action of a single lozenge is related to the required dosing interval.

Regulatory guidance mandates a minimum delay of two hours between each lozenge intake, which is intended to ensure the focused, local effect is maintained.


Q: Can older adults use Lysopain?

A: Lysopain is generally approved for use by adults.

However, official research documents indicate that the evidence is limited for characterizing treatment outcomes and physical comfort specifically in special populations, such as older adults.


Q: Does Lysopain interact with common vitamins or supplements?

A: Regulatory labels describe Lysopain as having negligible systemic absorption, meaning very little enters the bloodstream.

Due to this low systemic risk, there are no documented high-risk interactions listed for Lysopain with common vitamins or nutritional supplements.


Q: Can Lysopain cause tiredness or drowsiness?

A: According to the official safety profile, the documented adverse reactions are mainly localized effects in the mouth and throat, or involve allergic responses.

Central nervous system (CNS) effects, such as tiredness or drowsiness, are not listed in the documented adverse reactions.


Q: Is it normal to feel a mild headache when first starting Lysopain?

A: Official regulatory documents describing the safety profile of Lysopain lozenges do not list headache as a documented side effect.

The recorded adverse reactions focus on localized discomfort and allergic responses.


Q: Do I need to stop taking Lysopain before a planned surgery?

A: Official information describes the drug as having minimal potential for systemic absorption and does not document major systemic metabolic interactions.

The official safety profile does not include a regulatory warning to stop the medicine before surgery.


Q: Does Lysopain have a risk of dependence or addiction?

A: Lysopain is classified in regulatory documents as a Local Antiseptic and Enzybiotic.

Medicines that fall into this pharmacological category are not associated with a risk of dependence or addiction in the official safety profile.


Q: What happens if a child accidentally takes Lysopain?

A: Official instructions advise that, in the event of accidental ingestion, contact with a healthcare professional or poison control services is required.

The specific guidance provided by those professionals is the instruction to be followed.


Q: Why do official documents mention 'renal impairment' concerning Lysopain?

A: Official regulatory labels do not mention specific warnings or dosage adjustments related to renal impairment (kidney problems).

This is consistent with the drug's overall profile of having negligible systemic absorption into the body.


Q: What should I do if my side effects don't go away after a few days?

A: Regulatory information indicates that if symptoms, or any side effects, persist or worsen beyond the five-day treatment limit, consultation with a healthcare professional is advised.

This is consistent with the drug's short-term use constraint.


Q: Is it common for Lysopain to cause stomach upset?

A: The official safety profile lists adverse reactions related to Gastrointestinal disorders, but these are documented as local effects such as mouth discomfort.

There is no frequency provided for systemic (whole-body) symptoms like a traditional stomach upset.


Q: Can Lysopain be taken with other pain medications?

A: Regulatory information indicates there are no documented systemic interactions with most pain medications that are swallowed.

However, regulatory constraints advise caution against using Lysopain simultaneously with any other local antiseptic agents or oral treatments.


Q: Are there any known interactions between Lysopain and herbal remedies?

A: Since the medicine has negligible systemic absorption, official regulatory labels state there are no documented systemic interactions with herbal remedies or products.

The only interactions listed focus on preventing local interference in the mouth and throat.


Q: Does the time it takes to work depend on what I eat?

A: Official administration instructions focus on ensuring the lozenge melts slowly in the mouth to maximize mucosal contact time.

Official instructions recommend avoiding eating or drinking immediately after use to maximize the local effect.


Q: Is Lysopain safe for people with liver disease?

A: Official regulatory labels do not mention specific warnings or dosage adjustments related to liver disease.

This finding is consistent with the drug's overall profile of having negligible systemic absorption into the bloodstream.


Q: What does official research say about Lysopain and mood changes?

A: Studies summarized in official research reviews focus on symptomatic endpoints such as changes in pain intensity and difficulty swallowing.

These regulatory summaries do not document any research findings related to mood changes for this medicine.


Q: Why are some people concerned about driving while taking Lysopain?

A: The official safety profile for Lysopain is dominated by local and allergic reactions.

Because the documented adverse reactions do not include CNS effects like dizziness or drowsiness, an official warning regarding driving is not typically listed.


Q: Can Lysopain be used for chronic conditions?

A: Regulatory guidelines define Lysopain as a treatment intended for short-term symptomatic relief.

The official administration guidelines strictly limit the duration of treatment to five days or less, and prolonged use is contraindicated.


Q: Does Lysopain cause any change in appetite or weight?

A: Official regulatory documents outlining the safety profile of Lysopain do not list changes in appetite or weight as documented adverse reactions.


Q: How does the FDA or EMA classify Lysopain?

A: Official regulatory documents classify Lysopain as an Over-The-Counter (OTC) medicine.

It is classified for local use in the oral cavity and throat, falling within the Local Antiseptic pharmacological class.


Q: What does the term 'contraindication' mean for Lysopain users?

A: A contraindication is a medical term used in official labels to identify conditions or circumstances under which a drug should never be used.

For Lysopain, this includes conditions like a documented allergy to egg protein and age restrictions, where use is considered strictly prohibited due to potential harm.


Q: Does Lysopain affect sleep patterns?

A: The officially documented side effects of Lysopain primarily involve localized or allergic reactions.

Regulatory information does not list adverse effects on the central nervous system that would typically affect sleep patterns.


Q: Why is it important to tell my doctor all the medicines I take when starting Lysopain?

A: Official information recommends disclosing all medicines to a healthcare professional, even though Lysopain has a low systemic interaction risk.

This is primarily because simultaneous use with other local antiseptic agents or oral treatments is officially contraindicated to prevent local interference in the mouth and throat.

How should Lysopain be stored and disposed of?

How to Store and Dispose of Lysopain

Official regulatory guidelines strictly define the conditions necessary for storing Lysopain lozenges. The medicine must be stored at a temperature below 30°C (86°F) and kept in its original blister pack and outer carton to ensure protection from both light and moisture. Like all medications, it is mandated to store Lysopain out of the sight and reach of children.


Disposal Requirements

Disposal must adhere to specific instructions to protect the environment. Do not dispose of the medicine via household waste or wastewater (flushing down the toilet or sink). Unused or expired Lysopain should be returned to a pharmacist or collected via local authority programs, in accordance with local regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Lysopain found in:

A-Z Index: